Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
12 stocks to consider for the next leg of the bull market
07:45pm, Saturday, 14'th May 2022 MarketWatch
These companies are typically uncorrelated to indexes, giving investors a chance to outperform.
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
06:29pm, Friday, 13'th May 2022 Zacks Investment Research
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
10:20am, Thursday, 12'th May 2022 Zacks Investment Research
Sector ETF report for RYH
Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider
06:12pm, Wednesday, 11'th May 2022 Zacks Investment Research
Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
06:08pm, Wednesday, 11'th May 2022 Zacks Investment Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
2 No-Brainer Pharma Stocks to Buy Right Now
03:30pm, Wednesday, 11'th May 2022 The Motley Fool
Bristol-Myers Squibb and Johnson & Johnson have a lot to offer investors.
Worried About a Correction? Buy These 2 Evergreen Dividend Stocks
02:30pm, Wednesday, 11'th May 2022 The Motley Fool
Their businesses are rock-solid, and so are their dividend payments.
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for IHE
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Smart Beta ETF report for RYH
Vanguard Health Care Fund's Top 5 Trades in the 1st Quarter
05:05pm, Monday, 09'th May 2022
The Vanguard Health Care Fund (Trades, Portfolio) recently disclosed its first quarter 2022 portfolio, revealing that its top five trades for the quarter included a new position in Zoetis Inc. ( ZTS ,
Bristol-Myers Has the Stalest Product Line, Says Evaluate
03:07pm, Monday, 09'th May 2022
Unlike out-of-date bread, pharma companies don't usually throw out products that have become stale because many of them have long-term market relevance and will continue to be in demand for decades to
3 Safe Stocks to Buy That Are Crushing the Market
09:54am, Monday, 09'th May 2022 The Motley Fool
They perhaps, not so coincidentally, are all in the pharmaceutical business.
Nasdaq Bear Market: 3 No-Brainer Stocks to Buy During the Sell-Off
09:21am, Monday, 09'th May 2022 The Motley Fool
These stocks make for genius buys with the Nasdaq as much as 24% below its peak.
